These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21210111)

  • 21. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness.
    Heinrich S; Goerres GW; Schäfer M; Sagmeister M; Bauerfeind P; Pestalozzi BC; Hany TF; von Schulthess GK; Clavien PA
    Ann Surg; 2005 Aug; 242(2):235-43. PubMed ID: 16041214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative staging of lung cancer with combined PET-CT.
    Fischer B; Lassen U; Mortensen J; Larsen S; Loft A; Bertelsen A; Ravn J; Clementsen P; Høgholm A; Larsen K; Rasmussen T; Keiding S; Dirksen A; Gerke O; Skov B; Steffensen I; Hansen H; Vilmann P; Jacobsen G; Backer V; Maltbaek N; Pedersen J; Madsen H; Nielsen H; Højgaard L
    N Engl J Med; 2009 Jul; 361(1):32-9. PubMed ID: 19571281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial.
    Yi CA; Lee KS; Lee HY; Kim S; Kwon OJ; Kim H; Choi JY; Kim BT; Hwang HS; Shim YM
    Cancer; 2013 May; 119(10):1784-91. PubMed ID: 23423920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
    Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?
    Hayashi K; Abe K; Yano F; Watanabe S; Iwasaki Y; Kosuda S
    Ann Nucl Med; 2005 Jul; 19(5):393-8. PubMed ID: 16164196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
    Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
    Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualized positron emission tomography-based isotoxic accelerated radiation therapy is cost-effective compared with conventional radiation therapy: a model-based evaluation.
    Bongers ML; Coupé VM; De Ruysscher D; Oberije C; Lambin P; Uyl-de Groot CA
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):857-65. PubMed ID: 25752401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.
    van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; Verboom P; van Mourik JC; Postmus PE; Boers M; Teule GJ
    Lancet; 2002 Apr; 359(9315):1388-93. PubMed ID: 11978336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical impact of integrated FDG PET-CT on management decisions in patients with lung cancer.
    Subedi N; Scarsbrook A; Darby M; Korde K; Mc Shane P; Muers MF
    Lung Cancer; 2009 Jun; 64(3):301-7. PubMed ID: 19004519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of 2-[18F]fluoro-2-deoxyglucose positron emission tomography in preoperative management of solid-type small-sized lung cancer.
    Saisho S; Yasuda K; Maeda A; Yukawa T; Okita R; Hirami Y; Shimizu K; Nakata M
    Ann Nucl Med; 2013 Jul; 27(6):515-22. PubMed ID: 23504519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec.
    Nguyen VH; Peloquin S; Lacasse Y
    Can Respir J; 2005; 12(1):19-25. PubMed ID: 15776130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budget impact from the incorporation of positron emission tomography - computed tomography for staging lung cancers.
    Biz AN; Caetano R
    Rev Saude Publica; 2015; 49():57. PubMed ID: 26274871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Staging of non-small-cell lung cancer and application of FDG-PET. A cost modeling approach.
    Verboom P; Herder GJ; Hoekstra OS; Smit EF; van den Bergh JH; van Velthoven PC; Grijseels EW
    Int J Technol Assess Health Care; 2002; 18(3):576-85. PubMed ID: 12391950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
    Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
    Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer.
    Lejeune C; Bismuth MJ; Conroy T; Zanni C; Bey P; Bedenne L; Faivre J; Arveux P; Guillemin F
    J Nucl Med; 2005 Dec; 46(12):2020-8. PubMed ID: 16330566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results.
    Dietlein M; Weber K; Gandjour A; Moka D; Theissen P; Lauterbach KW; Schicha H
    Eur J Nucl Med; 2000 Nov; 27(11):1598-609. PubMed ID: 11105815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases.
    Wiering B; Adang EM; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Ruers TJ; Krabbe PF; Oyen WJ
    Nucl Med Commun; 2010 Nov; 31(11):938-44. PubMed ID: 20856152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
    Scott WJ; Shepherd J; Gambhir SS
    Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET/CT in non-small cell lung cancer staging-promises and problems.
    Devaraj A; Cook GJ; Hansell DM
    Clin Radiol; 2007 Feb; 62(2):97-108. PubMed ID: 17207691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in positron emission tomography technology have increased the need for surgical staging in non-small cell lung cancer.
    Lee BE; von Haag D; Lown T; Lau D; Calhoun R; Follette D
    J Thorac Cardiovasc Surg; 2007 Mar; 133(3):746-52. PubMed ID: 17320577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.